Drug Profile

Protexi - Celloram

Latest Information Update: 06 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Celloram
Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Sarcoma

Most Recent Events

29 Jul 2026 Pharmacodynamics data from preclinical trial in Sarcoma released by Celloram
29 Jul 2026 Celloram and University Hospitals Cleveland Medical Center plan to initiate a first-in-human clinical trial for Sarcoma
03 Aug 2023 Preclinical trials in Sarcoma in USA (Parenteral), prior to August 2023 (Celloram pipeline, August 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com